Active Not Recruiting OBSERVATIONAL NCT05938361

Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis (ZODIPSO)

Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis - ZODIPSO Study

Sponsor: Clin4all

Conditions Psoriasis Genital Psoriasis Nail Psoriasis Palmaris Psoriasis Plantaris Psoriasis of Scalp

Interventions Pruritus evaluation Psoriasis clinical assessments Quality of life evaluation Satisfaction assessment

Updated 5 times since 2023 Last updated: Sep 19, 2025 Started: Jun 1, 2023 Primary completion: Nov 1, 2024 Completion: Oct 15, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05938361, this observational or N/A phase trial focuses on Psoriasis Genital and Psoriasis Nail and remains ongoing. Sponsored by Clin4all, it has been updated 5 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Oct 2025 — Present [monthly]

Active Not Recruiting

Status: Unknown → Active Not Recruiting
Aug 2025 — Oct 2025 [monthly]

Unknown

Status: Recruiting → Unknown
Sep 2024 — Aug 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Aug 2023 — Jul 2024 [monthly]

Recruiting

First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clin4all

Data source: Clin4all

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France